BIO-TECHNE Corp vs Wheaton Precious Metals Corp — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Wheaton Precious Metals Corp trades at $138.2 (market cap $60.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 5.4× BIO-TECHNE Corp's market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Wheaton Precious Metals Corp for 66 Days on average.
| TECH | WPM | |
|---|---|---|
Market Cap | $11.37B | $60.84B |
Volume | 3,153,511 | 1,408,370 |
Sector | Health | Basic Materials |
52-Week High | $72.61 | $165.72 |
52-Week Low | $43.31 | $94.37 |
Typical Hold Time | 63 Days | 66 Days |
Enterprise Value | $11.40B | $62.71B |
Dividend Yield | 0.44% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Wheaton Precious Metals (WPM) trades at $134.96, down 1.95% on the day, amid a bearish technical signal. The company reported record revenues of $2.31B in 2025, with net income surging to $1.47B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights a growth strategy targeting 1.2 million ounces of production by 2030 through an expanded deal pipeline, supported by a fully funded capital plan.
The outlook remains positive with strong analyst support—80% recommend Buy and a consensus price target of $164.80 implies 22% upside. Key risks include execution of growth targets and sensitivity to gold/silver prices. The stock's current valuation multiples are elevated, but robust cash flow and margin expansion underpin the bullish case for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →